Prognostic role of inflammatory markers in hepatocellular cancer patients receiving sorafenib therapy

Ali Oğul¹*, Mahmut Büyükşimşek¹

Abstract

Objective: Systemic inflammatory markers have been shown to have prognostic value in many types of cancers. Although the prognostic role of the systemic immune-inflammation index (SII), derived neutrophil-lymphocyte ratio (dNLR) and platelet lymphocyte ratio (PLR) has been shown in hepatocellular cancer (HCC) patients who underwent transplantation, its prognostic value has not been investigated in HCC patients under sorafenib treatment. We investigated the prognostic value of inflammatory indices in patients with HCC under sorafenib treatment.

Materials and Methods: The data of 46 patients with stage III unresectable and stage IV HCC were evaluated retrospectively. SII and dNLR were dichotomized based on receiver operating characteristic (ROC) curve analysis (cut-off values: 355 and 1.8). No cut-off value could be determined for PLR; therefore, the median value was defined as the cut-off for PLR. At the time of diagnosis, values of these three inflammatory markers were analyzed to determine their association with clinicopathologic characteristics and to assess their prognostic values via the Kaplan-Meier method and multivariate Cox regression analysis.

Results: Overall survival (OS) was significantly shorter in patients with a high SII, dNLR, or PLR. In univariate analyses, tumor stage, tumor focus count, and presence of extrahepatic lesions seemed to affect survival. Multivariate analysis revealed SII and the presence of extrahepatic lesions as independent risk factors for survival.

Conclusion: The findings of the present study suggest that a high SII is an independent risk factor for survival in patients with HCC under sorafenib treatment.

Keywords: Sorafenib, hepatocellular cancer, systemic immune-inflammation index, derived neutrophil-lymphocyte ratio, platelet lymphocyte ratio

Introduction

Hepatocellular cancer (HCC) is the fourth leading cause of cancer-related death and leads to an annual number of fatalities around 800,000 worldwide (1). It is the ninth most common cancer in women and the fifth most common cancer in men (2). Treatment options include surgery, local ablative treatments, and systemic therapies for HCC. Sorafenib is an oral tyrosine kinase inhibitor that inhibits the rapidly accelerated fibrosarcoma (RAF) kinase and vascular endothelial growth factor (VEGFR) kinase pathways (3). Sorafenib was shown to improve overall survival (OS) and slow radiological progression of the disease compared with placebo in patients with Child Plough class A cirrhosis and inoperable HCC in the multicenter SHARP trial (4). Whereas adverse events related to treatment and decreases in baseline plasma biomarkers such as AST, ALT, and AFP have been proposed as prognostic markers of response to sorafenib, no marker has been widely accepted in this regard (5-7).
treatment in patients with advanced HCC under antiandrogen treatment. Based on all these findings, we aimed to investigate the role of SII, PLR, and dNLR in predicting survival in patients with HCC under sorafenib treatment.

Materials and Methods

Study population and definition

Patient data have been collected from their files and electronic records. A total of 46 patients with stage 4 or stage 3 inoperable HCC with respect to the eighth edition of American Joint Committee on Cancer (AJCC) TNM classification and also Child-Pugh class A cirrhosis and an AFP level above 20 ng/ml who were diagnosed radiologically or pathologically and were under sorafenib (Nexavar) treatment for a minimum of eight weeks were enrolled to this retrospective study.

Before the initiation of sorafenib treatment, all of the patients underwent an evaluation including complete blood count analysis; AFP; albumin, INR, and bilirubin (for Child-Pugh classification); and ultrasound to scan for the presence of ascites. For inclusion to the study, the patients had to have an Eastern Cooperative Oncology Group (ECOG) performance score of lower than two.

The age, sex, ECOG, PS, underlying liver disease, TNM stage, number of tumor foci in liver parenchyma on imaging, extrahepatic metastases, and pre-treatment laboratory values of the patients were recorded.

The initial dose of sorafenib was 400 mg bid. Sorafenib was discontinued only in case of disease progression or grade III unmanageable or grade IV toxicity. In the case of grade III manageable toxicity, sorafenib dose was reduced to 200 mg bid.

Sorafenib was discontinued in these patients only if grade III toxicity recurred under the reduced dose regimen. A decrease of more than 20% in AFP level after eight weeks of sorafenib treatment was defined as a response to treatment. In order to calculate pre-treatment SII, dNLR, and PLR values, respectively, platelet count X(neutrophil count/lymphocyte count), absolute neutrophil count/(white blood cell count-absolute neutrophil count) and platelet count/lymphocyte count formulas were used. The overall survival (OS) was calculated for all patients as the duration between the initiation of treatment and death or the last follow-up time for that patient.

Statistical analysis

To determine the cut-off values for SII and dNLR, ROC curve analysis was used. The log-rank test was used in univariate analyses, and Cox-regression model was used in multivariate analysis. Kaplan-Meier analysis was used to calculate OS duration, and survival graphics were presented. In the comparison of survival between groups, the log-rank test was used.

The variables consisted of age, sex, ECOG, PS, etiology, tumor stage, number of tumor foci, extrahepatic metastasis, albumin, SII, dNLR, PLR, the need for sorafenib dose modification, development of adverse events, response to sorafenib, and OS. No cut-off could be determined for PLR using ROC curve analysis, so its median value was used as the cut-off for PLR. Prognostic significance of SII, dNLR, and PLR were evaluated using univariate and multivariate analyses.

The odds ratio and 95% confidence interval were determined by cox regression analysis.

SPSS version 21.0 (IBM Inc., Chicago, IL, ABD) was used for statistical analyses. Statistical significance was set at p<0.05.

Results

Patient characteristics

A total of 46 patients with HCC who used sorafenib treatment were included. The most sensitive and specific values for study variables were determined using receiver-operating characteristics (ROC) curve analysis: cut-off values were 355 for SII and 1.8 for dNLR (Figure 1). The baseline characteristics of the patients are summarized in Table 1.

The median age was 58 (39-82), and 8.6% of the study population were females. Most of the patients (78.2%) had an ECOG PS of 0. The etiology of liver disease was HBV in 71.7% and HCV in 21.8%, and 4.3% of the study population reported alcohol use.

Survival outcomes

The median OS was 10.2 months, and the median duration of follow up was 9.8 months. In univariate analyses, the median OS was 10.8 months in stage III patients and 8.7 months in stage IV patients (p=0.024)

While patients with a single tumor focus had a median OS of 10.5 months, those with multiple tumor foci had a median OS of 9.6 months (p=0.047).

The patients with extrahepatic lesions had a median OS of 7.3 months, and those without extrahepatic lesions had a median OS of 10.4 months (p=0.011).

While the median OS was 11.7 months in the patients with an SII ≤355, it was 7.9 months in those with an SII >355 (p=0.008).

The median OS was 10.5 months in the patients with a dNLR ≤1.8, and it was 8.2 months in those with a dNLR >1.8 (p=0.025). The median OS was 10.2 months in the patients with a PLR ≤184 while it was 8.9 months in those with a PLR >184 (p=0.038). The patients with and without response to sorafenib had a median OS of 11.2 and 9.5 months, respectively (p=0.032).

There was no significant association between OS and age, sex, ECOG PS, etiology, albumin, need for sorafenib dose modification, and development of adverse events (p=0.117, p=0.145, p=0.684, p=1.125, p=1.187, p=0.251, and p=0.148, respectively). Multivariate analysis revealed that OS was independently associated with the presence of extrahepatic lesions and a high SII (p=0.014 and p=0.016, respectively, Table 2). Figure 2 demonstrates the survival graphs.
Table 1. Baseline characteristics in hepatocellular carcinoma patients treated with sorafenib (n=46)

|               | Number of patients n (%) |
|---------------|--------------------------|
| **Age**       |                          |
| ≤65           | 24 (52.1%)               |
| >65           | 22 (47.9%)               |
| **Gender**    |                          |
| Female        | 4 (8.6%)                 |
| Male          | 42 (91.4%)               |
| **ECOG PS**   |                          |
| 0             | 36 (78.2%)               |
| 1             | 10 (21.8%)               |
| **Etiology**  |                          |
| HBV           | 33 (71.7%)               |
| HCV           | 10 (21.8%)               |
| Alcohol       | 2 (4.3%)                 |
| Unknown       | 1 (2.2%)                 |
| **TNM stage** |                          |
| Stage III inoperable Stage IV | 9 (19.5%) |
| **Tumor focus count** |                  |
| Single        | 10 (21.8%)               |
| Multiple      | 36 (78.2%)               |
| **Extrahepatic lesion** |                |
| Yes           | 5 (10.8%)                |
| No            | 41 (89.2%)               |
| **Albumin <3.5 (g/dL)** |             |
| Yes           | 18 (39%)                 |
| No            | 28 (61%)                 |
| **WBC counts (x10^9/L), median(min-max)** | 7.25 (2.58-22.52) |
| **Neutrophil counts (x10^9/L), median(min-max)** | 2.37 (1.58-3.87) |
| **Lymphocyte counts (x10^9/L), median(min-max)** | 1.12 (0.68-1.76) |
| **Platelet counts (x10^9/L), median(min-max)** | 102.0 (65.2-278.0) |
| **SII**       |                          |
| ≤355          | 26 (56.5%)               |
| >355          | 20 (43.5%)               |
| **dNLR**      |                          |
| ≤1.8          | 18 (39.1%)               |
| >1.8          | 28 (60.9%)               |
| **PLR**       |                          |
| ≤184          | 25 (54.3%)               |
| >184          | 21 (45.7%)               |
| **Sorafenib dose modification** |            |
| Yes           | 8 (17.3%)                |
| No            | 38 (82.7%)               |
| **Adverse events** |                  |
| Grade III     | 5 (10.8%)                |
| Grade IV      | 1 (2.2%)                 |
| **OS (months), median (min,max)** | 10.20 (3.02-39.08) |
| **Response to sorafenib** |         |
| Yes           | 27 (58.6%)               |
| No            | 19 (41.4%)               |

ECOG PS: Eastern Cooperative Oncology Group Performance Score, TNM: Tumor Node Metastasis, WBC: White Blood Cell, SII: Systemic immune-inflammation index, dNLR: Derived neutrophil-lymphocyte ratio, PLR: platelet lymphocyte ratio, OS: Overall survival

Table 2. Univariable and multivariable analyses to predict overall survival in hepatocellular carcinoma patients

| Variables                     | Univariable | Multivariable |
|-------------------------------|-------------|---------------|
|                               | HR (95% CI) | P value       | HR (95% CI) | P value |
| Age greater than ≤65          | 1.419 (0.945-2.317) | 0.117         |              |
| Sex (Female vs male)          | 1.434 (0.914-2.436) | 0.145         |              |
| ECOG PS 0 vs 1                | 1.386 (0.748-2.187) | 0.684         |              |
| Etiology HBV vs HCV           | 1.681 (0.581-2.168) | 1.125         |              |
| TNM stage                     | 2.214 (1.108-3.847) | 0.024         | 0.912 (0.625-1.908) | 0.242 |
| Tumor focus count Single vs multiple | 1.194 (0.856-1.452) | 0.047         | 1.069 (0.875-1.365) | 0.358 |
| Extrahepatic lesion Yes vs no | 1.321 (0.682-2.654) | 0.011         | 1.258 (1.068-1.785) | 0.014 |
| Albumin <3.5 g/dL Yes vs no   | 1.654 (0.548-4.357) | 1.187         |              |
| SII ≤355 vs >355              | 2.914 (1.425-5.129) | 0.008         | 1.312 (1.057-1.456) | 0.016 |
| dNLR ≤1.8 vs >1.8             | 2.458 (1.015-3.587) | 0.052         | 1.275 (1.014-1.502) | 0.125 |
| PLR ≤184 vs 184               | 2.147 (1.915-5.478) | 0.038         | 1.354 (0.981-1.681) | 0.087 |
| Sorafenib dose modification Yes vs no | 1.528 (0.756-2.112) | 0.251         |              |
| Adverse events Yes vs no      | 1.451 (0.825-2.237) | 0.148         |              |
| Response to sorafenib Yes vs no | 2.328 (1.741-3.458) | 0.032         | 1.181 (0.764-1.385) | 0.343 |

Statistically significant p-values (<0.05). HR: Hazard ratio, CI: Confidence interval, ECOG PS: Eastern Cooperative Oncology Group Performance Score, TNM: Tumor Node Metastasis, SII: systemic immune-inflammation index, dNLR: derived neutrophil-lymphocyte ratio, PLR: platelet lymphocyte ratio.
Fig. 1. ROC analysis and AUC for sensitivity and specificity of inflammatory parameters: SII: systemic immune-inflammation index, dNLR: derived neutrophil lymphocyte ratio. SII-AUC:0.758 and dNLR-AUC:0.657

Fig. 2. Overall survival times according to inflammatory markers. SII: systemic immune-inflammation index (A), dNLR: neutrophil lymphocyte ratio (B), PLR: platelet lymphocyte ratio (C)
Discussion

CR is described as having a <5% BMPC ratio in addition to Hepatocellular cancer is a highly angiogenic tumor that develops in the setting of chronic inflammation and cirrhosis. The contributory role of inflammation in the development of cancer has long been studied, and recent studies focus on the effect of surrogate inflammatory markers on tumor dissemination and survival. Blood count parameter ratios have been used as markers predictive of tumor biology, aggressiveness, and other adverse outcomes associated with cancer (16). The vascular endothelial growth factor is released by platelets and neutrophils and plays an essential role in angiogenesis and tumor progression (17). Whereas the role of neutrophils in cancer pathogenesis is debated, they are known to take place in the microenvironment of various tumors such as HCC, renal cell carcinoma, and glioblastoma (18-20). On the other hand, lymphocytes release cytokines and prevent tumor progression by contributing to cytotoxic cell death (21). Sorafenib is an expensive anti-angiogenic multiple tyrosine kinase inhibitor that has been used in the treatment of HCC. In the present study, we aimed to evaluate the role of inflammatory indices, which are derived from complete blood count parameters, in predicting response to sorafenib treatment in patients with HCC. For this purpose, we investigated the predictive role of SII, dNLR, and PLR and found SII as an independent predictor of survival in these patients.

Inflammation is an essential step in the development of cancer and also a contributor to tumor progression. Inflammatory markers have been reported to be associated with poor survival and unresponsiveness to treatment in several solid organ cancers. In addition to thrombocytosis and neutrophilia, dNLR and PLR have been investigated in numerous studies in this regard (22). In 2012, Proctor et al. (23) reported that dNLR provided more prognostic information than NLR among more than ten thousand people with all cancer types (23). Li et al. (24) reported that a high dNLR was an independent prognostic factor in terms of survival and microvascular invasion in patients with HCC. In the present study, a high dNLR seemed to be associated with short survival time, but this association was not confirmed in the multivariate analysis.

Recently, the prognostic role of PLR has been investigated in patients with HCC who underwent hepatectomy or liver transplantation, and a high PLR before surgery has been found to be associated with HCC recurrence (25). To the best of our knowledge, the role of PLR in patients with HCC under sorafenib treatment has not been investigated in detail, and the findings of the present study may shed light on its role in this regard. Although it was not independently associated with survival in multivariate analysis, a high PLR was related to shorter survival in patients with HCC under sorafenib treatment in the present study.

It is not clear which physiological process affects SII. Neutrophils are associated with chemokines and proteases, which have a regulatory role in angiogenesis. These processes may affect blood circulation in tumors and tumor growth rate (26,27).

The platelets are able to release chemokines and cytokines. These cytokines may induce the proliferation of tumor cells (28). Lymphocytes play an important role in immune defense. A higher intensity of lymphocytes in the tumor microenvironment has been reported to be associated with better clinical outcomes and that these lymphocytes are related to circulating lymphocytes (29). A high lymphocyte ratio has also been reported to be associated with a better prognosis in several cancer types, and circulating lymphocytes may inhibit tumor metastasis and proliferation (30,31).

The systemic immune-inflammation index has been reported as an excellent prognostic index in patients with small-cell lung cancer, esophageal cancer, and renal cell carcinoma (13,32,33). In the present study, we investigated the prognosis value of SII in patients with HCC under sorafenib treatment, and our findings suggest that it is an independent predictor of survival.

The present study has several limitations. Firstly, it was a retrospective study with small sample size. Secondly, SII levels may be influenced by conditions such as acute infections and chronic viral infections. Nonetheless, it is not easy to determine an optimal cut-off for inflammatory markers because of the individual variation in the immune response. Therefore, the change in baseline SII level may be a better predictor than a constant cut-off. It may be rational to compare the prognostic value of the change in SII levels after treatment rather than a constant cut-off in further prospective studies.

Conclusion

The findings of the present study are important in terms of the independent association between SII levels and survival in patients with HCC under sorafenib treatment. We suggest that using SII to predict survival in HCC patients under sorafenib treatment may prove beneficial provided that our findings are confirmed in prospective studies.

Acknowledgments, Funding: None

Conflict of interest and financial disclosure: The authors declare that there is no conflict of interest and financial relationships.

Author’s contributions: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Ali Oğul. The first draft of the manuscript was written by Mahmut Büyüksimsek, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Conceptualization: Ali Oğul, Methodology: Mahmut Büyüksimsek; Formal analysis and investigation: Mahmut Büyüksimsek; Writing - original draft preparation: Ali Oğul; Writing - review and editing: Mahmut Büyüksimsek; Supervision: Mahmut Büyüksimsek.

Conflict of interest and financial disclosure: The authors declare that there is no conflict of interest and financial relationships.
**Ethical issues:** Author declare, originality and ethical approval of research. The study was conducted under defined rules by the Local Ethics Commission guidelines and audits.

**References**

1. Fitzmaurice C, Akinyemiju T, Abere S, Ahmed M, Alam N, Alemany MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.

2. Ferlay J, Soerjomataram I, Dikshit R, Eser E, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

3. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–8.

4. Rovestgi G, Orsi G, Kallipto A, Vivaldi C, Marsili G, Faloppi L, et al. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointest Tumors. 2019;6(3):92–107.

5. Reig M, Torres F, Rodriguez-Lopez C, Forner A, Llarch N, Rimola J, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol [Internet]. 2014;61(2):318–24. Available from: http://dx.doi.org/10.1016/j.jhep.2013.03.030

6. Bettinger D, Schultheiß M, Knüppel E, Thrumme R, Blum HE, Spangenberg HC. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56(2):789–90.

7. Llovet JM, Peña CEA, Lathia CD, Shaan M, Meinhardt G, Brux J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–300.

8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

9. Zhong J-H, Huang D-H, Chen Z-Y. Oncotarget 75381. www.impactjournals.com/oncotarget Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget [Internet]. 2017;8(43):75381–8. Available from: www.impactjournals.com/oncotarget/

10. Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11(3):2241–8.

11. Yamada Y, Sakamoto S, Rui J, Yamamoto S, Kamada S, Imamura Y, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020(Febuary).

12. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.

13. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236(4):297–304.

14. Lolli C, Caffo O, Scarpi E, Aiesta M, Conteduca V, Maines F, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol. 2016;7(OCT):1–7.

15. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116(19):4590–6.

16. Ismael FN, Forde J, Mills E, Khan W, Cabrera R. Utility of inflammatory markers in predicting hepatocellular carcinoma survival after liver transplantation. Biomed Res Int. 2019;2019:5–8.

17. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–49.

18. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Landbeck F, Von Der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709–17.

19. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol [Internet]. 2011;54(5):948–55. Available from: http://dx.doi.org/10.1016/j.jhep.2010.08.041

20. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999;98(4):349–54.

21. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28(26):4045–51.

22. Russo A, Franchina T, Ricciardi R, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (DNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. J Cell Physiol. 2018;233(10):6337–43.

23. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer [Internet]. 2012;107(4):695–9. Available from: http://dx.doi.org/10.1038/bjc.2012.292

24. Li P, Huang W, Wang F, Ke YF, Gao L, Shi KQ, et al. Nomograms based on inflammatory biomarkers for predicting tumor grade and micro-vascular invasion in stage II/III hepatocellular carcinoma. Vol. 38, Bioscience Reports. 2018.

25. Liu L, Gong Y, Zhang Q, Cai P, Feng L. Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis. Front Oncol. 2020;9(January):1–10.

26. Kusumanto YH, Dam WA, Hopsers GAP, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer [Internet]. 2012;107(4):695–9. Available from: http://dx.doi.org/10.1038/bjc.2012.292

27. Coobs-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating endothelial growth factor. Angiogenesis. 2003;6(4):283–7.

28. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446–58.

29. Gil-Bernabe AM, Ferjančič Š, Tlalka M, Zhao L, Allen PD, Im JH, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012;119(3):3164–75.

30. Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of Regulatory T Cells Is Increased in Patients with Pancreas or Breast Adenocarcinoma. J Immunol. 2002;169(5):2756–61.

31. Clark JE, Conner S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Neutrophil lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. Hpb. 2007;9(6):456–60.
31. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010;25(12):1427–33.

32. Feng JF, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. Med (United States). 2017;96(4):0–5.

33. Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016; 7:54564-71. https://doi.org/10.18632/oncotarget.10515.